Parasite Polyamines as Pharmaceutical Targets

Curr Pharm Des. 2017;23(23):3325-3341. doi: 10.2174/1381612823666170601101644.

Abstract

There is an urgent need for the identification and validation of new therapeutic targets in protozoan parasites because currently available drugs are limited in number and usefulness, and no vaccines are available. The discovery that alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, is an efficacious treatment for African Sleeping Sickness caused by the protozoan parasite Trypanosoma brucei, has validated the polyamine pathway as a target in protozoan parasites. Polyamines are ubiquitous organic cations that play critical roles in key cellular processes such as growth, differentiation, and macromolecular biosynthesis. In recent years, remarkable progress has been made in the characterization of the polyamine pathway in a variety of protozoan parasites and this review will highlight surprising and unique features that could lead to new therapeutic strategies.

Keywords: Leishmania; Plasmodium; Polyamines; Trypanosoma brucei; Trypanosoma cruzi; parasites; therapeutic strategies.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Drug Delivery Systems / methods*
  • Humans
  • Parasites / drug effects*
  • Parasites / metabolism
  • Polyamines / antagonists & inhibitors*
  • Polyamines / metabolism
  • Protozoan Proteins / antagonists & inhibitors*
  • Protozoan Proteins / metabolism
  • Trypanosoma brucei brucei / drug effects
  • Trypanosoma brucei brucei / metabolism
  • Trypanosomiasis, African / drug therapy
  • Trypanosomiasis, African / metabolism

Substances

  • Antiprotozoal Agents
  • Polyamines
  • Protozoan Proteins